GSK Risk Management
GSK风险管理代写 GlaxoSmithKline is a global healthcare British organization aiming to help people feel better, do more, and live longer.
Contents
1. Introduction
2.Aims of the organization (GSK)
3.Risk
3.1. Opportunities and Threats
3.2. Existing controls
3.3. Calculation of risk and risk Threshold
3.4. Mitigation Actions
4.Conclusion
5.References
1. Introduction.
In the current digital world, every organization is required to maintain sustainable growth and development for survival. To maintain sustainable growth and development, every organization minimizes its risks and capitalizes on the current opportunities. GlaxoSmithKline is a global healthcare British organization aiming to help people feel better, do more, and live longer.
The study shows the impact of enterprise risk management programs on organizational financial performance.
The study reveals that enterprise resource management is positively related to organizational value. In all factors, firm size, Tobin, Q, and institutional ownership are positively related to enterprise risk management while negatively related to assets opacity and leverage. Thus enterprise risk management is very crucial for the growth and success of any organization. Moreover, an increase in Firm value indicates the sustainable development of the organization. Thus all organizations need to identify their risks and opportunities and minimize or control their risks (Hoyet and Liebenberg, 2011).
Another study explains the relation of the enterprise risk management system and firm financial performance. They evaluate the relationship of 112 US firms who are disclosing their information regarding enterprise risk management. The results reveal that firm complexity, firm size, environmental uncertainty, industry competition, and board of directors monitoring are highly correlated with enterprise risk management. Thus organizations need to maintain a proper risk management system that minimizes their risk and increases financial performance. Furthermore, the study explains that enterprise risk management is not only beneficial in the short run but also provide benefit in the long run (Tseng et al., 2009).
译文：
内容 GSK风险管理代写
1. 简介
2.组织目标（GSK）
3.风险
3.1.机会与威胁
3.2.现有控制
3.3.风险和风险阈值的计算
3.4.缓解措施
4。结论
5.参考资料
一、介绍
在当前的数字世界中，每个组织都需要保持可持续增长和发展才能生存。为了保持可持续增长和发展，每个组织都尽量减少风险并利用当前的机会。葛兰素史克是一家全球性的英国医疗保健组织，旨在帮助人们感觉更好、做得更多、活得更久。
研究显示了企业风险管理计划对组织财务绩效的影响。
研究表明，企业资源管理与组织价值呈正相关。在所有因素中，企业规模、Tobin、Q 和机构所有权与企业风险管理正相关，而与资产不透明度和杠杆负相关。因此，企业风险管理对于任何组织的成长和成功都非常重要。此外，公司价值的增加表明组织的可持续发展。因此，所有组织都需要识别他们的风险和机会，并尽量减少或控制他们的风险（Hoyet 和 Liebenberg，2011）。
另一项研究解释了企业风险管理系统与企业财务绩效的关系。他们评估了 112 家披露企业风险管理信息的美国公司之间的关系。结果表明，企业复杂性、企业规模、环境不确定性、行业竞争和董事会监督与企业风险管理高度相关。因此，组织需要维护适当的风险管理系统，以最大限度地降低风险并提高财务绩效。此外，该研究解释说，企业风险管理不仅在短期内有益，而且在长期内也有益（Tseng et al., 2009）。
This study explores the impact of enterprise risk management on organizational success.
For this purpose, the researcher evaluates 1100 US firms for a period of five years from 2011 to 2015. The results show that all factors are highly correlated with enterprise risk management except organizational culture. Furthermore, the study explains that an enterprise risk management system needs every global organization to ensure smooth operations and profit. In addition, the study shows that those firms are highly successful who disclose information regarding their enterprise risk management system (Dikenson, 2001).
They explore the relationship between the early stage of enterprise risk management implementation systems in the US and international firms and different organizational factors. For this purpose, the authors evaluate 123 firms of US and international. The results reveal that enterprise risk management implementation is positively correlated to the presence of four big auditors, the presence of a Chief risk officer, an independent board, support of CEO and CFO, and the presence of entities in the banking, education, and insurance industry. Finally, they conclude that enterprise risk management is the key point for success and sustainable development. All organizations need to develop and maintain an enterprise risk management framework and follow (Hermanson et al., 2005).
This study explores the relationship between organizational dynamics and enterprise risk management.
They study the data of three firms through a longitudinal case study method for a period of seven years. The results describe that organizational dynamics are highly correlated with the enterprise risk management system. Furthermore, they show that enterprise risk management is essential for any organizational survival in the current complex and competitive environment of business. Each business must have its own ERM system. Finally, they conclude that enterprise risk management has a massive impact on organizational dynamics (Azzone et al., 2010).
They explain the relationship between enterprise risk management and firm financial performance. For this purpose, the researchers evaluate different factors of 100 international firms. The results show a mixed impact. Some of the factors are highly correlated with enterprise risk management, while some show a negative association. Furthermore, the study explains that international organizations are highly sensitive to different risks. Therefore they must have a good risk management framework to appropriately respond to each risk and avoid any damage or loss associated with that risk. Finally, the study concludes that the ERM system boosts organizational performance and creates value in the long run (Rustambekov et al., 2011).
译文：
本研究探讨了企业风险管理对组织成功的影响。 GSK风险管理代写
为此，研究人员在 2011 年至 2015 年的五年时间里对 1100 家美国公司进行了评估。结果表明，除组织文化外，所有因素都与企业风险管理高度相关。此外，该研究还解释说，企业风险管理系统需要每个全球组织来确保顺利运营和盈利。此外，研究表明，那些披露有关其企业风险管理系统信息的公司非常成功（Dikenson，2001）。
他们探讨了美国和国际公司早期企业风险管理实施系统与不同组织因素之间的关系。为此，作者评估了 123 家美国和国际公司。结果显示，企业风险管理实施与四大审计师的存在、首席风险官的存在、独立董事会、CEO和CFO的支持以及银行、教育和保险实体的存在正相关行业。最后，他们得出结论，企业风险管理是成功和可持续发展的关键。所有组织都需要开发和维护企业风险管理框架并遵循（Hermanson 等，2005）。
本研究探讨了组织动态与企业风险管理之间的关系。
他们通过纵向案例研究方法研究了三家公司的数据，为期七年。结果表明，组织动态与企业风险管理系统高度相关。此外，他们表明企业风险管理对于任何组织在当前复杂和竞争激烈的商业环境中的生存都是必不可少的。每个企业都必须有自己的 ERM 系统。最后，他们得出结论，企业风险管理对组织动态有巨大影响（Azzone 等，2010）。
他们解释了企业风险管理和公司财务绩效之间的关系。为此，研究人员评估了 100 家国际公司的不同因素。结果显示了混合的影响。一些因素与企业风险管理高度相关，而另一些则呈现负相关。此外，该研究还解释说，国际组织对不同的风险高度敏感。因此，他们必须有一个良好的风险管理框架来适当地应对每一种风险，并避免与该风险相关的任何损害或损失。最后，该研究得出结论，ERM 系统从长远来看可提高组织绩效并创造价值（Rustambekov 等人，2011 年）。
2. Aims of the organization (GSK).
GlaxoSmithKline is a UK based global healthcare organization that aims:
√ To help people feel better.
√ To do more.
√ To live longer.
Thus the aims of the GlaxoSmithKline clear their vision. They are the only healthcare company that provides the latest and technology-based healthcare solutions to make people’s lives better than before. GlaxoSmithKline not only provides healthcare solutions but also help people financially to make their life easy and better through various programs like scholarships and charity. (GSK, 2019). GSK, through their missions, provide different services to their stakeholders.
They also consider environment-related issues; hence they initiated a program green world that provides planting trees in different countries of the world. Thus by planting trees, GSK helps the world to resolve environmental issues. GSK also help disabled people by providing them wheelchairs or artificial organs or other equipment that can help them in their life. Thus in this way, GSK contributes to society by helping people and their surrounding environment. Hence the aims of the GSK are very clear.
译文：
2. 组织目标（GSK） GSK风险管理代写
葛兰素史克是一家总部位于英国的全球医疗保健组织，其目标是：
√ 帮助人们感觉更好。
√ 做得更多。
√ 活得更久。
因此，葛兰素史克的目标明确了他们的愿景。他们是唯一一家提供最新和基于技术的医疗保健解决方案的医疗保健公司，使人们的生活比以前更美好。葛兰素史克不仅提供医疗保健解决方案，而且还通过奖学金和慈善等各种计划帮助人们在经济上使他们的生活更轻松、更美好。 （葛兰素史克，2019 年）。 GSK 通过他们的使命，为他们的利益相关者提供不同的服务。
他们还考虑与环境相关的问题；因此，他们发起了一项绿色世界计划，在世界不同国家提供植树服务。因此，通过植树，葛兰素史克帮助世界解决环境问题。 GSK 还通过为残疾人提供轮椅或人工器官或其他可以帮助他们生活的设备来帮助他们。因此，葛兰素史克通过帮助人们及其周围环境来为社会做出贡献。因此，GSK 的目标非常明确。
3. Risk.
The probability that actual results will differ from expected results is known as risk. (William et al., 2017).
Risk is the uncertainty that the actual outcome will deviate from the expected outcome. (Jonsen and Yang, 2011).
The authors describe the relationship between different organizational risks and their impact on organizational value. The results show that all types of internal risks are positively related to organizational value, but some external risks have no impact on organizational value. In addition, they explain that not all types of risks occur in all cases, but some of them are associated with special circumstances, and as the circumstance fulfill, they occur; otherwise, they do not show their impact (Nocco and Stulz, 2006).
Risks are the hurdles that make any organization damage or stop operations. Hence every organization needs to properly analyze and develop a system that can control their risk to survive the industry. Many organizations fail during their startup because of their risk associated with them. Thus to grow, every organization must know its risks associated with them. Without accurate information regarding every area of their business, no business can grow and flourish. Thus an enterprise risk management system helps deal with all types of risk and professionally controls them.
译文：
3. 风险 GSK风险管理代写
实际结果与预期结果不同的概率称为风险。 （威廉等人，2017 年）。
风险是实际结果会偏离预期结果的不确定性。 （Jonsen 和 Yang，2011 年）。
作者描述了不同组织风险之间的关系及其对组织价值的影响。结果表明，所有类型的内部风险都与组织价值呈正相关，但部分外部风险对组织价值没有影响。此外，他们解释说，并非所有类型的风险都发生在所有情况下，但其中一些风险与特殊情况有关，并随着情况的发展而发生；否则，它们不会显示其影响（Nocco 和 Stulz，2006 年）。
风险是使任何组织受损或停止运营的障碍。因此，每个组织都需要正确分析和开发一个可以控制其风险的系统，以在行业中生存。许多组织在启动期间失败，因为与他们相关的风险。因此，要发展壮大，每个组织都必须了解与其相关的风险。如果没有有关其业务各个领域的准确信息，则任何业务都无法发展和繁荣。因此，企业风险管理系统有助于应对所有类型的风险并对其进行专业控制。
3.1. Opportunities and Threats.
Opportunities and threats are always considered beneficial for the organization because they provide help in organizational growth.
a. Opportunities (GSK).
The following are the opportunities for GSK.
Changing demographics, Advances in science and technology, Pricing and access, Regulatory environment, and societal expectations.
i. Changing Demographics.
Changing demographics show a huge demand for healthcare products because the world population is projected to increase till 2030, about 8.8 billion. Thus increasing population means increasing demand for therapeutic and preventative health care products.
ii. Advances in Science and technology.
Rapid development in science and technology is transforming the health sector. Thus new inventions in cell therapy technologies and other health-related technologies show opportunities. Advancement in functional genomic like CRISPR also ensures other drug discoveries.
iii. Pricing and access. GSK风险管理代写
Highly demanding inventions are required for providing quality health care products. As new technology is very costly, thus availing new technology with minimum price in an opportunity for GSK. Seeking those markets where new technology is low in price with high quality.
iv. Regulatory environment.
Healthcare is a hugely regulated industry where public expectations reflect health products that comply with health, safety, and quality. GSK is closely monitors and where relevant and required to improve regulations in the US, Europe, and the UK.
v. Societal Expectations.
Business expectations are rapidly changing. Despite financial benefits, businesses are expecting to create value for their stakeholders by working for environmental and social issues. GSK is responding to 13 key areas for providing benefits to their stakeholder as expectations are changing; hence GSK is responding accordingly.
译文：
3.1.机会和威胁 GSK风险管理代写
机会和威胁总是被认为对组织有利，因为它们为组织发展提供帮助。
a. 机会（GSK）
以下是葛兰素史克的机会。
不断变化的人口统计、科学技术进步、定价和获取、监管环境和社会期望。
i. 不断变化的人口统计数据。
不断变化的人口结构显示出对医疗保健产品的巨大需求，因为预计到 2030 年世界人口将增加约 88 亿。因此，人口增加意味着对治疗性和预防性保健产品的需求增加。
ii.科学技术进步。
科学技术的快速发展正在改变卫生部门。因此，细胞治疗技术和其他健康相关技术的新发明展示了机会。 CRISPR 等功能基因组的进步也确保了其他药物的发现。
iii. 定价和访问。
提供高质量的保健产品需要高要求的发明。由于新技术非常昂贵，因此以最低的价格利用新技术为 GSK 提供了机会。寻求新技术低价高品质的市场。
iv. 监管环境。
医疗保健是一个受到严格监管的行业，公众的期望反映了符合健康、安全和质量的健康产品。 GSK 密切监控并在相关和需要时改进美国、欧洲和英国的法规。
v. 社会期望。
业务期望正在迅速变化。尽管有经济利益，但企业希望通过解决环境和社会问题为其利益相关者创造价值。随着期望的变化，葛兰素史克正在响应 13 个关键领域为其利益相关者提供利益；因此，葛兰素史克正在做出相应的回应。
b.Threats (GSK).
Principal threats of GlaxoSmithKline are patient safety, product quality, financial controls & reporting, anti-bribery & corruption, commercial practices, privacy, research practices, third party oversight, environment, health & safety, and sustainability, information security, and supply continuity. Our risk management framework is designed to support our long-term priorities (GSK, 2019 Page 43- 46 & 275- 287)
i. Patient safety.
“Failure to appropriately collect, review, follow up, or report human safety information, including adverse events from all potential sources, and to act on any relevant findings on time”.
ii. Product quality.
“Failure by GSK, its contractors or suppliers to ensure:–Appropriate controls and governance of quality in product development, Compliance with good manufacturing practice or good distribution practice regulations in commercial or clinical trials manufacture and distribution activities, Compliance with the terms of GSK product licenses and supporting regulatory activities.”
iii. Financial controls and reporting.
“Failure to comply with current tax laws or incurring significant losses due to treasury activities; failure to report accurate financial information in compliance with accounting standards and applicable legislation.”
iv. Anti-bribery and corruption (ABAC).
“The ABAC risk comprises five sub-risk areas:–Bribery of public officials by GSK, Bribery of commercial and other non-public entities by GSK, Bribery by third parties acting on behalf of GSK, GSK employees receiving and requesting bribes and other undue personal benefit, Other corruption-non-compliance with laws and regulations related to money laundering or facilitation of tax evasion by third parties/clients/partners.”
译文：
b. 威胁 (GSK)。 GSK风险管理代写
葛兰素史克的主要威胁是患者安全、产品质量、财务控制和报告、反贿赂和腐败、商业实践、隐私、研究实践、第三方监督、环境、健康和安全以及可持续性、信息安全和供应连续性。我们的风险管理框架旨在支持我们的长期优先事项（GSK，2019 页 43-46 和 275-287）
i. 患者安全。
“未能适当收集、审查、跟进或报告人类安全信息，包括来自所有潜在来源的不良事件，并及时对任何相关发现采取行动”。
ii.产品质量。
“葛兰素史克、其承包商或供应商未能确保：– 在产品开发中对质量进行适当控制和治理，在商业或临床试验制造和分销活动中遵守良好制造规范或良好分销规范法规，遵守 GSK 产品条款许可证和支持监管活动。”
iii. 财务控制和报告。
“未能遵守现行税法或因财务活动而蒙受重大损失；未能按照会计准则和适用法律报告准确的财务信息。”
iv. 反贿赂和腐败 (ABAC)。
“ABAC 风险包括五个子风险领域：– GSK 贿赂公职人员、GSK 贿赂商业和其他非公共实体、代表 GSK 行事的第三方贿赂、GSK 员工收受和索取贿赂以及其他不当行为个人利益、其他腐败——不遵守与洗钱或协助第三方/客户/合作伙伴逃税有关的法律法规。”
v. Commercial practices.
“Failure to engage in commercial activities that are consistent with the letter and spirit of the law, industry, or the Group’s requirements relating to marketing and communications about our medicines and associated therapeutic areas; appropriate interactions with healthcare professionals (HCPs) and patients; and legitimate and transparent transfer of value.”
vi. Privacy.
“The failure to collect, secure, use, and destroy personal information (PI) in accordance with data privacy laws can lead to harm to individuals and GSK, including fines and operational, financial and reputational risk.”
vii. Research practices.
“Research practices risk is the failure to adequately conduct ethical and sound pre-clinical and clinical research. In addition, it is the failure to engage in scientific activities that are consistent with the letter and spirit of the law and industry, or the Group’s requirements. It comprises the following sub-risks: Non-clinical & laboratory research; Human subject research; Data integrity; Care, welfare and treatment of animals; Human biological samples management; Data disclosure; Regulatory filings and engagement; Scientific engagement; and Intellectual property”. GSK风险管理代写
viii. Third-party oversight (TPO).
“There is a risk that our third parties fail to meet their contractual, regulatory or ethical obligations resulting in significant operational, reputational, legal and financial risk for GSK (and in some cases our employees directly). Put, and there is a risk that third parties fail to deliver the goods and services we expect or fail to deliver them in a legal and compliant way”.
ix. Environment, health, and safety & sustainability.
“Failure in management of the execution of hazardous activities; GSK’s physical assets and infrastructure; handling and processing of hazardous chemicals and biological agents; control of releases of substances harmful to the environment in both the short and long term; leading to incidents which could disrupt our R&D and Supply activities, harm employees, harm the communities we operate in and harm the environment and its longer-term sustainability.”
x. Information security.
“The risk that unauthorized disclosure, theft, unavailability or corruption of GSK’s information or key information systems may lead to harm to our patients, workforce, and customers, disruption to our business and loss of commercial or strategic advantage, damage to our reputation or regulatory sanction.”
xi. Supply continuity.
“Failure to deliver a continuous supply of the compliant finished product; inability to respond effectively to a crisis incident on time to recover and sustain critical operations.”
译文：
v. 商业惯例。 GSK风险管理代写
“未能从事符合法律、行业或集团关于我们的药物和相关治疗领域的营销和传播要求的文字和精神的商业活动；与医疗保健专业人员 (HCP) 和患者的适当互动；以及合法和透明的价值转移。”
vi.隐私。
“未能根据数据隐私法收集、保护、使用和销毁个人信息 (PI) 可能会对个人和 GSK 造成伤害，包括罚款以及运营、财务和声誉风险。”
vii.研究实践。
“研究实践风险是未能充分进行合乎道德和合理的临床前和临床研究。此外，未能从事符合法律和行业的文字和精神或集团要求的科学活动。它包括以下子风险： 非临床和实验室研究；人类学科研究；数据的完整性;动物的护理、福利和治疗；人体生物样本管理；数据披露；监管备案和参与；科学参与；和知识产权”。
viii.第三方监督 (TPO)。
“我们的第三方可能无法履行其合同、监管或道德义务，从而导致 GSK（在某些情况下直接给我们的员工）带来重大的运营、声誉、法律和财务风险。并且存在第三方无法交付我们期望的商品和服务或无法以合法合规的方式交付的风险。”
ix. 环境、健康、安全和可持续性。
“管理危险活动的执行失败； GSK 的实物资产和基础设施；危险化学品和生物制剂的处理和加工；控制对环境有害的物质的短期和长期释放；导致的事件可能会扰乱我们的研发和供应活动，伤害员工，伤害我们经营所在的社区，并损害环境及其长期可持续性。”
x. 信息安全。
“GSK 信息或关键信息系统的未经授权披露、盗窃、不可用或损坏可能导致我们的患者、员工和客户受到伤害、我们的业务中断以及商业或战略优势的丧失、我们的声誉或监管机构受损的风险制裁。”
xi.供应连续性。
“未能持续供应合规成品；无法及时有效地应对危机事件以恢复和维持关键运营。”
3.2. Existing controls.
Shimpi et al. (2015) tested the association between enterprise risk management and firm financial performance. For this purpose, the researchers evaluate 500 Canadian firms. They used the availability of the Chief risk officer and risk committee as a proxy. The results explain that enterprise risk management is highly correlated with return on assets and stock price increase. Furthermore, the study explains that those firms’ stock price volatility decrease has managed a proper enterprise risk management framework and regularly discloses information regarding their risk management system. Finally, they conclude that a proper risk management system is crucial for every organization to remain successful. GSK风险管理代写
GSK is a global organization and maintains and plan for every situation to hedge their organization. For this purpose, they have some measures which are given below:
1.GSK has a huge global network of quality and compliance professionals from lower management to top management. They oversee and provide solutions from site level to top management to ensure quality and operational compliance.
2.Financial results are reviewed by regional management and then the financial controller and Chief financial officer. Thus they evaluate business financial health and plan accordingly.
3. GSK风险管理代写
The Anti-corruption board was created in 2019 to control the risk of corruption. For this purpose, the board committee includes board representatives from all functional areas.
4.GSK design new strategic objectives that are compliant with commercial practices and can launch new products that are competitive and resource effectively.
5.GSK has a privacy governance board headed by a Chief compliance officer who oversees GSK’s overall data privacy operating model.
6.GSK has a global policy framework that enables them to deal with third parties, and it applies to all employees and contractors.
7.GSK, s corporate executive team is responsible for environment, health, safety, and sustainability-related issues. They oversee and ensure an effective control system.
8.GSK has a global information security policy that enables them the control of information security risk.
9.The supply chain model in the pharmaceutical, vaccine, and healthcare business in such a way that ensures the delivery of quality products globally as far as possible.
译文：
3.2.现有控制。 GSK风险管理代写
Shimpi 等人。 (2015) 测试了企业风险管理与公司财务绩效之间的关联。为此，研究人员评估了 500 家加拿大公司。他们使用首席风险官和风险委员会的可用性作为代理。结果说明企业风险管理与资产回报率和股价上涨高度相关。此外，该研究解释说，这些公司股价波动的下降管理了适当的企业风险管理框架，并定期披露有关其风险管理系统的信息。最后，他们得出结论，适当的风险管理系统对于每个组织保持成功至关重要。
GSK 是一家全球性组织，并针对每种情况进行维护和计划，以对冲其组织。为此，他们采取了一些措施，如下所示：
1.GSK 拥有庞大的全球质量和合规专业人员网络，从基层管理人员到高层管理人员。他们监督并提供从站点级别到最高管理层的解决方案，以确保质量和运营合规性。
2.财务业绩由区域管理层审核，然后由财务总监和财务总监审核。因此，他们评估企业财务状况并相应地制定计划。
3.
反腐败委员会成立于 2019 年，旨在控制腐败风险。为此，董事会委员会包括来自所有职能领域的董事会代表。
4.GSK设计符合商业惯例的新战略目标，能够推出具有竞争力和资源有效的新产品。
5.GSK 设有一个由首席合规官领导的隐私治理委员会，负责监督 GSK 的整体数据隐私运营模式。
6.GSK 拥有全球政策框架，使他们能够与第三方打交道，并适用于所有员工和承包商。
7.GSK 的企业执行团队负责环境、健康、安全和可持续发展相关问题。他们监督并确保有效的控制系统。
8.GSK拥有全球信息安全政策，使他们能够控制信息安全风险。
9.制药、疫苗和医疗保健业务的供应链模式，以确保尽可能在全球范围内交付优质产品。
3.3. Calculation of risk and risk Threshold.
GSK has a developed framework for managing their risks. They have a professional team that identifies risk and their nature and then provides a suitable solution to avoid or control it. Thus the nature of risk determines the action strategy.
The study explains different risk management models. They evaluate different models to increase organizational performance. The authors explain that the enterprise risk management system is a full package for increasing organization performance. Furthermore, they explain that the enterprise risk management framework enables organizations to control their all-risk and increase their organization performance. In addition, the authors also express that some organizations manage their risk in such a way that not only save their organization but also provide benefit to the industry and stakeholders too (Olson and Wu, 2010).
They explain the enterprise risk management system in a global context.
The authors explain that enterprise risk management systems provide strength to the health of the organization, save at from threats, and help in capitalizing new opportunities. They further add that risk is very dangerous for any organization. Sometimes it gives small losses but sometimes it collapses a business. In addition, they provide solutions for managing a proper and strong risk management system that can hedge the organization from any risk. Finally, they conclude that a proper risk management system framework not only hedges organizations against risks but also provides different opportunities to grow and develop (Merkley et al., 2001).
译文：
3.3.风险和风险阈值的计算。 GSK风险管理代写
GSK 拥有一套成熟的风险管理框架。他们有一个专业的团队来识别风险及其性质，然后提供合适的解决方案来避免或控制它。因此，风险的性质决定了行动策略。
该研究解释了不同的风险管理模型。他们评估不同的模型以提高组织绩效。作者解释说，企业风险管理系统是提高组织绩效的完整方案。此外，他们解释说，企业风险管理框架使组织能够控制其所有风险并提高其组织绩效。此外，作者还表示，一些组织管理风险的方式不仅可以挽救组织，还可以为行业和利益相关者带来利益（Olson 和 Wu，2010）。
他们在全球范围内解释了企业风险管理系统。
作者解释说，企业风险管理系统为组织的健康提供了力量，避免了威胁，并有助于利用新机会。他们进一步补充说，风险对任何组织来说都是非常危险的。有时它会造成很小的损失，但有时它会使企业倒闭。此外，它们还提供了管理适当而强大的风险管理系统的解决方案，可以对冲组织的任何风险。最后，他们得出结论，一个适当的风险管理系统框架不仅可以对冲组织风险，还可以提供不同的成长和发展机会（Merkley 等，2001）。
3.4. Mitigation Actions.
GSK has a professional team for risk management, and they provide mitigation actions to control or avoid risks. GSK provides them following mitigation actions, s professional team for risks as mentioned above.
1.Their chief medical officer is responsible for patient safety. The chief medical officer has a Safety governance board that evaluating and ensuring human safety. Thus, they are ultimately focusing their patients to ensure their health and happiness through different health care products.
2.GSK has a global professional team that ensures quality products. They have a representative from the site level to top management to oversee and ensure quality compliance with international standers.
3.GSK controls its financial affair through a highly competitive authority, financial controller and chief financial officer, and regional management. They oversee and plan their financial matters accordingly and control all risks associated with this area to avoid any loss.
4. GSK风险管理代写
GSK has an anti-corruption board that controls and oversees all their corruption-related matters. Anti-corruption board control all risk related to the business employees from lower-level staff to top management.
5.GSK has set up new strategic objectives to cover their commercial practices related activities. They set new standards that are compliant with international standards to launch new products compliant with international standards and policies.
6.GSK’s global policy framework enables them to interact with their suppliers and contractors appropriately. This policy is applicable to all employees and contractors.
7.GSK, s corporate executive team oversees and controls environment, health, safety, and sustainability-related matters. They correctly identify risk and provide solutions to it.
8.GSK global information policy framework enables them to control or quickly respond to any risk information security-related. Any information related risk can harm the organization in short as well as in the long run. Thus quick response is required in the current world of information technology.
9.The supply chain model of GSK is very strong that enables them to deliver their healthcare and vaccine-related products worldwide as far as possible.
译文：
3.4.缓解措施。 GSK风险管理代写
GSK 拥有专业的风险管理团队，他们提供缓解措施以控制或避免风险。 GSK 为他们提供以下缓解措施，即上述风险的专业团队。
1.他们的首席医疗官负责患者的安全。首席医疗官有一个安全治理委员会，负责评估和确保人类安全。因此，他们最终将重点放在患者身上，通过不同的保健产品来确保他们的健康和幸福。
2.GSK拥有全球专业团队，确保产品质量。他们有一个从现场级别到最高管理层的代表来监督和确保质量符合国际标准。
3.GSK通过竞争激烈的权威、财务总监和首席财务官以及区域管理来控制其财务事务。他们相应地监督和计划他们的财务事项，并控制与该领域相关的所有风险以避免任何损失。
4.
GSK 设有一个反腐败委员会，负责控制和监督所有与腐败相关的事务。反腐败委员会控制与业务员工相关的所有风险，从基层员工到高层管理人员。
5.GSK 设立了新的战略目标，以涵盖其商业实践相关的活动。他们制定符合国际标准的新标准，推出符合国际标准和政策的新产品。
6.GSK 的全球政策框架使他们能够与供应商和承包商进行适当的互动。本政策适用于所有员工和承包商。
7.GSK 的企业执行团队监督和控制环境、健康、安全和可持续发展相关事宜。他们正确识别风险并提供解决方案。
8.GSK全球信息政策框架使他们能够控制或快速应对任何与信息安全相关的风险。任何与信息相关的风险都可能在短期和长期损害组织。因此，在当前的信息技术世界中需要快速响应。
9. GSK 的供应链模式非常强大，使他们能够尽可能地在全球范围内交付其医疗保健和疫苗相关产品。
4.Conclusion.
In the current digital world, every organization needs to grow and maintain sustainable development. Thus to grow and make continuous development, organizations need to control their risks and capitalize on their opportunities. Hence every organization must have its strong enterprise risk management system framework for sustainable development.
GSK is a global healthcare business that provides healthcare products that comply with international standards worldwide. They have different boards regarding all business matters. They deal with all areas of business and their issues; specifically, they manage risks associated with each area of the business. So GSK has a well-developed enterprise risk management framework. Therefore they are successful in their business. Thus enterprise risk management system is very crucial for the sustainable development of any organization.
译文：
4. 结论。 GSK风险管理代写
在当前的数字世界中，每个组织都需要成长并保持可持续发展。 因此，为了成长和持续发展，组织需要控制风险并抓住机遇。 因此，每个组织都必须拥有强大的企业风险管理系统框架以实现可持续发展。
GSK 是一家全球医疗保健企业，提供符合全球国际标准的医疗保健产品。 他们在所有业务事项上都有不同的董事会。 他们处理所有业务领域及其问题； 具体来说，他们管理与每个业务领域相关的风险。 所以葛兰素史克拥有完善的企业风险管理框架。 因此，他们在业务上取得了成功。 因此，企业风险管理系统对于任何组织的可持续发展都至关重要。
5. References
Hoyt, R.E., and Liebenberg, A.P., 2011. The value of enterprise risk management. Journal of Risk and insurance, 78(4), pp.795-822.
Nocco, B.W., and Stulz, R.M., 2006. Enterprise risk management: Theory and practice. Journal of applied corporate finance, 18(4), pp.8-20.
Gordon, L.A., Loeb, M.P. and Tseng, C.Y., 2009. Enterprise risk management and firm performance: A contingency perspective. Journal of accounting and public policy, 28(4), pp.301-327.
Dickinson, G., 2001. Enterprise risk management: Its origins and conceptual foundation. The Geneva Papers on Risk and Insurance. Issues and Practice, 26(3), pp.360-366.
Beasley, M.S., Clune, R., and Hermanson, D.R., 2005. Enterprise risk management: An empirical analysis of factors associated with the extent of implementation. Journal of accounting and public policy, 24(6), pp.521-531.
Arena, M., Arnaboldi, M., and Azzone, G., 2010. The organizational dynamics of enterprise risk management. Accounting, Organizations, and Society, 35(7), pp.659-675.
McShane, M.K., Nair, A., and Rustambekov, E., 2011. Does enterprise risk management increase firm value?. Journal of Accounting, Auditing & Finance, 26(4), pp.641-658.
Grace, M.F., Leverty, J.T., Phillips, R.D., and Shimpi, P., 2015. The value of investing in enterprise risk management. Journal of Risk and Insurance, 82(2), pp.289-316.
Miccolis, J.A., Hively, K., and Merkley, B.W., 2001. Enterprise risk management: Trends and emerging practices. Altamonte Springs, FL: Institute of Internal Auditors Research Foundation.
Olson, D.L. and Wu, D.D., 2010. Enterprise risk management models(p. 15). BerlingHeilderbeg: Springer.
其他代写：essay代写 英国代写 assignment代写 analysis代写 code代写 assembly代写 作业代写 CS代写 Data Analysis代写 data代写 澳大利亚代写 app代写 algorithm代写 作业加急 homework代写 Exercise代写 加拿大代写 北美代写 北美作业代写
合作平台：essay代写 论文代写 写手招聘 英国留学生代写
